7 Sep 2023 14:57
7 September 2023
ECO Animal Health Group plc ("the Company")
(AIM: EAH)
Result of Annual General Meeting
ECO Animal Health Group plc announces that at its Annual General Meeting held earlier today ("AGM") all resolutions proposed to the meeting were duly passed.
Proxy votes received in relation to each resolution were as follows:
Resolution | For |
% |
Discretionary |
% | Against |
% | Withheld |
01 | 40,393,039 |
99.996 |
Nil |
0.000 | 1,594 |
0.004 | Nil |
02 | 37,377,701 |
92.531 |
3,384 |
0.008 | 3,013,548 |
7.460 | Nil |
03 | 40,386,195 |
99.979 |
Nil |
0.000 | 8,187 |
0.020 | 251 |
04 | 40,393,039 |
99.996 |
Nil |
0.000 | 1,594 |
0.004 | Nil |
05 | 40,392,788 |
99.995 |
Nil |
0.000 | 1,594 |
0.004 | 251 |
06 | 40,383,756 |
99.973 |
Nil |
0.000 | 5,877 |
0.014 | 5,000 |
07 | 40,383,756 |
99.973 |
Nil |
0.000 | 5,877 |
0.014 | 5,000 |
Contacts:
ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)
| 020 8447 8899 |
IFC Advisory Graham Herring Zach Cohen
| 020 3934 6630
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Philip Davies George Tzimas Sam Butcher
|
020 7496 3000 |
Investec (Joint Broker) Gary Clarence Carlo Spingardi Lydia Zychowska
|
020 7597 5970
|
Equity Development Hannah Crowe Matt Evans | 020 7065 2692 |
About ECO Animal Health
ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.
Eco Animal (EAH)